IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels
Acquisition strengthens EY’s Veeva Centers of Excellence, expanding clinical, regulatory, and commercial services for global pharma and biotech companies
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
ExellenS applies optimized facility designs, equipment, and processes across all sites to ensure equivalency and speed
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles
The collaboration combines the extensive CMC expertise of Sai Life Sciences in API development, Agility Life Sciences in formulation development, and Centrix Pharma Solutions in drug product development and clinical manufacturing
This collaboration aims to combine Molcure’s cutting-edge AI technology with Boehringer Ingelheim’s extensive expertise in drug discovery
Subscribe To Our Newsletter & Stay Updated
